Jan 10 (Reuters) - Glaukos Corp:
* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT
* GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018
* GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN
* GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017 